抗酸治疗联用降低系统性硬化症患者霉酚酸酯的生物利用度:一项交叉试验
该序贯交叉试验纳入20例稳定使用霉酚酸酯(MMF,1.5-3 g)的系统性硬化症(SSc)患者,依次接受单用MMF、联用雷尼替丁、联用埃索美拉唑各1个月。与单用MMF相比,联用埃索美拉唑使霉酚酸(MPA)平均AUC降低32.7%(平均差22.28 μg h ml-1),联用雷尼替丁降低21.97%(平均差14.93 μg h ml-1),两药均显著降低总胃肠道评分。
要点
- SSc患者联用埃索美拉唑使MPA平均AUC降低32.7%,联用雷尼替丁降低21.97%。
- 联用雷尼替丁或埃索美拉唑均显著降低总胃肠道评分。
- 作者认为联用质子泵抑制剂或H2受体阻滞剂时需监测MMF药物水平。
核心结论
- 联用质子泵抑制剂(PPI)或H2受体阻滞剂(HRB)可显著降低SSc患者MMF的生物利用度。
- 作者认为联用这些药物时需监测MMF药物水平以避免治疗失败。
研究设计与样本
- 序贯交叉试验纳入20例稳定使用MMF(1.5-3 g)的SSc患者,第1个月单用MMF,第2、3个月分别联用雷尼替丁和埃索美拉唑。
- 每月末计算MPA的12小时AUC和总胃肠道评分,并在各治疗组间比较。
- 试验注册号:CTRI/2020/06/025,939。
主要发现
- 与单用MMF相比,联用埃索美拉唑使MPA平均AUC降低32.7%(平均差=22.28 μg h ml-1)。
- 与单用MMF相比,联用雷尼替丁使MPA平均AUC降低21.97%(平均差=14.93 μg h ml-1)。
- 联用雷尼替丁或埃索美拉唑均显著降低总胃肠道评分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Mycophenolate mofetil (MMF) is an effective treatment option for interstitial lung disease (ILD) in systemic sclerosis (SSc). Many patients require co-administration of proton pump inhibitors (PPI) or H2 receptor blockers (HRB) because of various gastrointestinal (GI) manifestations in SSc. Co-treatment with PPI or HRB have shown to reduce serum drug levels in post-transplant patients. We wanted to see if there is a similar phenomenon for Mycophenolate in SSc. METHODS: Twenty SSc patients, who were on a stable dose of MMF (1.5-3 g) underwent a sequential cross over study with MMF alone in the first month, followed by co-treatment with Ranitidine and then Esomeprazole in the second and third month respectively. Estimation of 12-hour area under curve (AUC) of Mycophenolic Acid (MPA) levels and total GI score were calculated at the end of each month and compared between the treatment arms. [Trial registration: CTRI/2020/06/025,939] RESULTS: Co-administration of esomeprazole was associated with 32.7% (mean difference = 22.28 μg h ml-1) reduction in mean AUC MPA, whereas ranitidine caused a reduction of 21.97% (mean difference = 14.93 μg h ml-1) in MPA AUC when compared to MMF without anti-acid therapies. The addition of ranitidine or esomeprazole resulted in significant reduction in the total GI score. CONCLUSION: Co-administration of PPI or HRB can significantly reduce the bioavailability of MMF in patients with SSc. To avoid therapeutic failure of MMF drug level monitoring is essential when these agents are co-prescribed with MMF.
引用
- Alex G, Shanoj KC, Varghese DR, et al. Co prescription of anti-acid therapy reduces the bioavailability of mycophenolate mofetil in systemic sclerosis patients: A crossover trial. Semin Arthritis Rheum. 2023. PMID: 37820508. doi:10.1016/j.semarthrit.2023.152270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。